Observing gut health in children with leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to observe how leukemia treatment affects gut health, specifically the microbiome, and how quickly recovery occurs post-treatment. It will monitor the nutritional status and gut health of children aged 0-16 undergoing treatment for acute myelogenous leukemia (AML), hemophagocytic lymphohistiocytosis (HLH), or Burkitt lymphoma/leukemia. Measurements will be taken during routine medical appointments at Great Ormond Street Hospital, focusing on the impact of nutrition and feeding on gut recovery. The study seeks to understand the relationship between chemotherapy-induced intestinal mucositis and overall recovery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \- Consented to partake in the study
* Aged 0-16 years old
* Diagnosed with AML/HLH/ Burkits

Exclusion Criteria:

* 17 years old + (treated at UCL adolescent unit)
* Inflammatory bowel disease: ulcerative colitis or Crohn's disease
* Children who had previously been treated with chemotherapy in another institution age

Where it's running

• Great Ormond Street Hospital
  London, United Kingdom Recruiting

Study contacts

• Study coordinator: Graeme O'Connor, PhD
• Email: graeme.oconnor@nhs.net
• Phone: +4474059200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• National Egyptian HLH Registry for pediatric patients

  A national HLH registry is being created in Egypt to collect information about pediatric HLH patients to improve understanding and care.

  Recruiting Ain Shams University · Cairo and 1 other locations · NCT07800234

• CG009301 for adults with relapsed or treatment‑resistant blood cancers

  This trial will try a new drug called CG009301 to see if it's safe and helps adults whose leukemia or related blood cancers have come back or not responded to prior treatment.

  Recruiting at 3 sites Phase 1 Cullgen (Shanghai),Inc · Nanchang and 2 other locations · NCT07347171

• Sulforaphane to speed blood‑cell recovery after long‑frozen cord‑blood transplant

  This trial tries sulforaphane to see if it helps adults with high‑risk AML, ALL, or MDS recover blood cells faster after receiving cord blood units frozen for 10 years or more.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjing · NCT07297576

• Venetoclax blood levels and treatment toxicity during hypomethylating-agent combinations for AML in remission

  This study will see if venetoclax blood levels are linked to side effects in people with AML who are in remission and receiving hypomethylating agents plus venetoclax.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Pavia · NCT07254312

• Therapy plan for children with Down syndrome and acute myeloid leukemia in Russia

  This trial will test a standardized four-course chemotherapy program for children (0–18) with AML and Down syndrome in Russia to try to improve survival and reduce treatment side effects.

  Recruiting Phase 3 Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow · NCT07232134

• Donor-derived γδ T cell therapy for MRD-positive AML after stem-cell transplant

  This trial tests whether giving donor-derived γδ T cells can help adults with MRD-positive AML after an allogeneic stem-cell transplant.

  Recruiting Early Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Beijing · NCT07126782

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.